Phase I study to evaluate the safety and efficacy of resveratrol in enhancing the function of natural killer cells

Phase 1

• Conditions: immune insufficiency, hematologic malignancy, solid tumor

• Registration Number: JPRN-UMIN000007690
• Lead Sponsor: Kanazawa University Hospital

Brief Summary

The administration of MES resulted in a significant increase in the antioxidant activity of the plasma and a decrease in the protein carbonyl content of the plasma compared with the corresponding baseline levels. The circulating numbers of B and T lymphocytes remained essentially unchanged throughout the course of the study, however MES consumption was associated with an increase in the proportion of circulating NK cells and regulatory T cells (CD3+, CD4+, CD25, CD127low/neg).

Detailed Description

Not available

Study Timeline

• Study Start: 2012-04-09
• Study Completion: 2013-03-01
• Results First Posted: 2015-11-05
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

Not provided

Exclusion Criteria

Any of the following: currently receiving a drug therapy, currently having chronic diseases such as heart, lung, kidney, gastrointestinal, and inflammatory diseases, suffering from invasive cancer within five years, suffering from non-invasive cancer within a year, and a history of smoking within one year.

Study & Design

• Study Type: Interventional
• Study Design: Not specified